Experience in CRRT using PRISMA monitor in the ICU of a university hospital in Northeast Mexico

Journal of Nephrology & Therapeutics

ISSN: 2161-0959

Open Access

Experience in CRRT using PRISMA monitor in the ICU of a university hospital in Northeast Mexico

4th International Conference on Nephrology & Therapeutics

September 14-16, 2015 Baltimore, USA

Rizo-Topete Lilia Mar?­a

Universidad Autonoma de Nuevo Leon, Mexico

Posters-Accepted Abstracts: J Nephrol Ther

Abstract :

Introduction: The AKI appears in 5-25% of patients in ICU, of which 6% will require RRT. If the AKI is associated with MODS mortality will be 50% and if RRT is required this will be 80%. Sepsis and Acute tubular perfusion are causes of AKI. The CRRT is an option for hemodynamically unstable patients and those who cannot handle the volume or metabolic disorders. The hemodialysis (HD) in critical patients is a common practice; however, the use of continuous therapy with hemodiafiltration modality requires special characteristics. Objective: To describe the experience using PRISMA monitor in our center. Material & Methods: Retrospective, descriptive, observational study. All patients were given CRRT with PRISMA at our center from March 2013 to November 2014. Data analysis was performed using Excel and SPSS programs. There is no conflict of interest and was conducted according to the ethics committee of our hospital. Results: CRRT was applied in an active way to 18 patients, 15 males (83%) and 3 females (17%), the average age was 43.9 years (Min. 17 Max. 78). 14 presented AKIN III, 4 where known with CKD. The most common cause of AKI was septic shock (83.3%). The oliguric AKI was the most common form of presentation in 86% of the patients. The average days of stay in ICU was 17.5 (SD 16.5). The average days of arrival and development of AKI is 2.6 days (SD 2.9). APACHE II and SOFA admission average was 30.5 (SD 6.5) and 13.6 (of 3.9) respectively. It was possible to stop CRRT in 5 of 18 patients (27.7 %), 2 patients continued with HD. There was a patient with combined therapy PRISMAMARS. Only 3 out of 18 patients (20%) survived the hospital stay. In the comparative analysis of the groups: Survivors versus non survivors, there were no statistically significant differences in the SOFA and APACHE II scores or in the days of stay in the ICU with IC of 95%. As for the prescription, blood flow measured in ml/min, extraction measured in ml/hr, the dialysate, the reinjection and total UF, showed no statistically significant differences with IC of 95%. Discussion & Conclusions: According to the results, our experience is similar to that reported in the literature with high mortality in patients with AKI and MODS, despite improvement in renal function. With the methodology used and the present number of patients, it?´s not possible to point out a good or bad prediction factor on the clinical characteristics of the patients or the therapeutic prescription.

Biography :


Google Scholar citation report
Citations: 784

Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report

Journal of Nephrology & Therapeutics peer review process verified at publons

Indexed In

arrow_upward arrow_upward